(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A definitive Bike Standoff: Decision in favor of Your Number one Ride - 2Manual for Tracking down Special Store Lodgings
- 3Creative Do-It-Yourself Ventures for Each Expertise Level
- 4Vote In favor of Economical Way You Prescribe to Shop for Garments
- 5Manual for Tracking down Financial plan Amicable Travel Objections
- 6 U.S. States for Climbing
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- Figuring out Significant Regulations and Guidelines for Organizations
- How comfort foods trigger pleasure in our brains
- Favored Vehicle for Seniors: Make Your Determination
- Vote in favor of Your Number one kind of pie
- 5 Pizza Fixings That Characterize Your Character
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Civil rights leader Jesse Jackson hospitalized
